Background. Both poor residual renal function (RRF) and high fibroblast growth factor 23 (FGF-23) levels are associated with arterial stiffness, left ventricular hypertrophy and increased (cardiovascular) mortality. Whether FGF-23 and RRF are interrelated is unknown. Methods. We performed a prospective observational cohort study in 35 peritoneal dialysis (PD) patients with evaluation at 1, 6, 12 and 24 months after start of PD. In addition, the role of RRF was assessed in a cross-sectional observational cohort study including 68 prevalent haemodialysis patients. Results. RRF significantly declined over time in PD patients. This decline was parallelled by a significant increase of both serum phosphorus and FGF-23 levels. In the prevalent dialysis cohort, RRF was found to be inversely associated with serum FGF-23 levels, independent of dialysis vintage, dialytic creatinine clearance, estimates of dietary phosphate intake (i.e. normalized protein nitrogen appearance), active vitamin D therapy and serum phosphorus and calcium levels. RRF, serum phosphorus and calcium levels and active vitamin D therapy explain 69% of the variation in FGF-23. The 38 anuric patients had higher FGF-23 levels but similar serum phosphorus levels. Conclusions. We demonstrate an important association between RRF and FGF-23, independent of classical determinants. This favours the hypothesis that the ailing kidney directly contributes to the raised FGF-23 levels. Whether FGF-23 is associated with poor outcomes independent of RRF, or vice versa, remains to be clarified.
Introduction
Residual renal function (RRF), being substantial in most patients at the time dialysis is started, inevitably declines as dialysis vintage increases [1] . This time course is unfortunate as it is increasingly recognized that RRF significantly contributes to the overall health and well-being of dialysis patients. It not only provides small solute clearance but also plays an important role in maintaining fluid balance [2] and removal of middle molecules and protein-bound uraemic toxins [3, 4] . Decline of residual renal function also contributes significantly to anaemia, inflammation and malnutrition in patients on dialysis. Finally, residual renal function is significantly associated with a better phosphorus control, at least in peritoneal dialysis (PD) patients [5] . Fibroblast growth factor 23 (FGF-23) is a recently identified important player in phosphorus metabolism. FGF-23 is primarily secreted by osteocytes [6] . It has several endocrine effects on mineral metabolism: it induces phosphaturia [7] , reduces circulating levels of calcitriol [7] and inhibits secretion of parathyroid hormone (PTH) [8] . FGF-23 levels progressively increase as glomerular filtration rate declines beginning in the early stage of chronic renal disease [9, 10] , with some investigators observing significant increases already by Stages 2-3 disease [9, 11] . By the time patients reach dialysis, levels can be up to 1000-fold higher than in healthy individuals [12] .
Both poor residual renal function and high FGF-23 are associated with arterial stiffness, cardiovascular calcification, left ventricular hypertrophy and increased (cardiovascular) mortality [13] [14] [15] [16] [17] . Whether RRF and serum FGF-23 levels are interrelated has not been studied so far.
The present study aimed to investigate the association between RRF and FGF-23 levels. We therefore performed a longitudinal prospective study in incident PD patients and a cross-sectional study in prevalent haemodialysis (HD) patients.
Materials and methods

Study population
Thirty-five incident PD (19 male, age 57 AE 17 years) and 68 prevalent HD (36 male, age 70 AE 12 years) patients were enrolled in the present study.
PD patients were recruited from an ongoing prospective observational study (NCT01306149). Only patients with a technique survival exceeding 2 years and no missing visits were selected for inclusion in the present analysis. All patients were routinely started on a continuous ambulatory PD (CAPD) regimen with four exchanges of conventional lactate-buffered glucose solutions (Dianeal 1.36%; Baxter, Lessines, Belgium) (i.e. the socalled 'full-dose regimen'). Automated PD using a cycler was started later, depending on patient preference. After an initial in-hospital training period of~1 week, patients were followed at the outpatient clinic at 6-to 8-weeks intervals. At each visit, clinical parameters, biochemistry and Kt/V and creatinine clearance were assessed to guide dialytic and medical therapy. A total weekly Kt/V !1.7 was aimed for (adequacy target) and normovolaemia was targeted using loop diuretics, hypertonic glucose solutions (Dianeal 3.86%; Baxter) and/or the polyglucose icodextrin (Extraneal; Baxter), as judged appropriate by the treating physician.
HD patients, free of active infectious or cardiovascular disease, were randomly selected from our dialysis unit. All patients were dialysed thrice weekly using high-flux membranes (polysulphone, 1.8-2.4 m 2 ; Fresenius Medical Care, Bad Homburg, Germany). The study was approved by the ethical committee of the University Hospitals Leuven and informed consent was obtained from all patients.
Study visits and procedures
PD patients were assessed 1, 6, 12 and 24 months after start of PD. At each visit, urine and peritoneal drainage, collected during the preceding 24-h period, were weighed and sampled and a midday blood sample was obtained.
HD patients were assessed only once, during a mid-week dialysis session. Dialysis duration was 238 AE 31 min. The blood flow was 299.5 AE 41.5 mL/min. Dialysate flow was always 500 mL/min. Total ultrafiltration amounted to 2029 AE 875 mL. Single-pool tKt/V amounted to 1.6 AE 0.3. A pre-dialysis blood sample was taken and urine collected in the ensuing inter-dialytic interval was weighed and sampled. All samples were stored at À80°C until analysis.
Demographics and maintenance mineral metabolism therapy were recorded at all visits. Of note, all HD patients received native vitamin D supplements as part of routine dialysis practice.
Analytical techniques
Serum full-length FGF-23 levels were determined with a sandwich enzymelinked immunosorbent assay (Kainos Laboratories, Inc., Tokyo, Japan) with two different monoclonal antibodies directed against the N-terminal and C-terminal portions of FGF-23 (Kainos Laboratories, Inc.). Calcidiol and calcitriol levels were measured using a radioimmunoassay [18, 19] . Serum concentrations of PTH were determined by an immunoradiometric assay, as described elsewhere [20] . Creatinine (Cr), urea nitrogen (UN), calcium (Ca) and phosphorus (P) were measured using standard assays. The measured serum Ca levels were adjusted to albumin levels [21] .
Calculations and definitions
RRF was estimated by calculating the arithmetic mean of renal urea nitrogen and creatinine clearance and expressed in mL/min/1.73m 2 . Anuria was defined as 24-h urine output <100 mL and/or RRF <1 mL/min/1.73m 2 . In PD patients, peritoneal (dCl solute ), renal (rCl solute ) and total (tCl solute ) clearances normalized to 1.73m 2 of body surface area (litres per week per 1.73m 2 ) were calculated for creatinine, urea nitrogen and phosphorus by means of direct determination from dialysis fluids, urine and midday serum solute concentrations. Peritoneal, renal and total Kt/V were calculated only for urea nitrogen (Kt/V UN ). Body surface area was estimated by using the Du Bois and Du Bois method [22] . The distribution volume of urea nitrogen (V) was assessed using the formula of Watson et al. [23] for total body water. Normalized protein nitrogen appearance (nPNA) was calculated according to Bergström et al. [24] .
Statistics
Data are expressed as mean AE SD or median (interquartile range), as appropriate. Differences in prevalent HD patients (anuric versus non-anuric) and in PD patients (M1 versus M24) were evaluated using the (un)paired t-test or their non-parametric analogues (as appropriate) and chi-square test of association for continuous and categorical data, respectively. Simple linear regression analyses were used to examine associations. Non-parametric distributed analytes were ln-transformed to achieve normality for the regression analyses. Multivariate linear regression analysis was performed including all univariately associated variables (P < 0.2). After excluding colinearity, the best subset of variables was selected by backward elimination on P <0.05. The linear mixed model (LMM) approach was used to model time courses of solute concentrations and their clearances in PD patients. Dialysis vintage, defined as number of months from the start of PD treatment, was introduced as a fixed effect. By using random effects, the model allowed for interindividual variation of the intercept and slope of time courses. The linearity assumption, an essential condition for the use of LMM, was checked for all variables. Non-linear data were ln-transformed for the LMM analysis. In order to include all variables, ln-transformation of renal clearances was done on renal clearances values 11. Two-sided P <0.05 was considered statistically significant. The SAS version 9.2 (SAS Institute, Cary, NC) software programme was used for statistical analysis.
Results
Prospective observational study
Patient and PD characteristics, mineral metabolism therapy and biochemistry at the various study visits are summarized in Table 1 . RRF significantly declined over time, whereas serum levels of phosphorus and FGF-23 significantly increased. FGF-23 levels almost doubled between M1 and M24 (P ¼ 0.002). Hyperphosphataemia, defined by a serum phosphorus level >5.6 mg/dL, was observed in 5.7% (M1), 22.9% (M6), 8.6% (M12) and 28.6% (M24) of patients. Serum PTH, calcidiol and calcitriol did not show significant changes. Dietary protein intake, as estimated by nPNA, dry body weight and serum albumin levels did not change either. Figure 1 shows the evolution of the Kt/V UN and solute clearances over time. Total weekly Kt/ V UN and total clearances of urea nitrogen and creatinine significantly decreased. This decrease can be attributed solely to the loss of RRF, as dialytic Kt/V UN and clearances remained stable. The decrease of total weekly Kt/V UN was modest (from 2.3 to 2.1). Total Kt/V UN exceeded the target of 1.7 in >85% of the patients at all time points. Total phosphorus clearance also decreased over time, but significance was not reached. At M1, RRF contributed up to 60.1, 51.2 and 38.0% of total clearance of creatinine, phosphorus and urea nitrogen, respectively. At M24, RRF contributed up to 48.1, 40.7 and 28.7% of total clearances of creatinine, phosphorus and urea nitrogen, respectively.
Essentially, the same observations were made in a subset of patients (n ¼ 15) free of active vitamin D therapy during the whole study period (data not shown).
Cross-sectional study
Patient characteristics, mineral metabolism therapy and biochemistry of patients enrolled in the cross-sectional study are summarized in Table 2 . The median dialysis vintage was 18 months. The mean RRF amounted to 1.3 mL/min/ m 2 . Serum FGF-23 levels were higher in anuric as compared to non-anuric HD patients (P ¼ 0.08), despite similar serum phosphorus and PTH levels and despite more intensive phosphate binder therapy. Table 3 shows the results of the regression analysis. In univariate analysis, increased serum phosphorus (albumin corrected), serum calcium and active vitamin D therapy and decreased RRF were each significantly associated with increased serum FGF-23; serum phosphorus was the strongest univariate predictor. In the multivariate model, decreased RRF and increased serum phosphorus, calcium and active vitamin D therapy were found to be independently associated with increased serum FGF-23. These variables explain 69% of the variation of FGF-23 (P < 0.001).
Discussion
The major finding of the present study is that residual renal function shows a strong, inverse and independent relationship with serum phosphorus and FGF-23 levels in dialysis patients.
The kidney plays an important role in phosphorus excretion. As renal function declines, phosphorus homeostasis is maintained through a compensatory decrease in renal tubular reabsorption, mediated partly by the phosphaturic hormones PTH and FGF-23. This adaptation allows serum phosphorus levels to remain within the normal range until glomerular filtration rate drops <30 mL/min. Our data clearly show that the kidney remains important for phosphorus control after the initiation of maintenance dialysis. Firstly, in a prospective observational study including 35 incident PD patients, we observed a significant increase of serum phosphorus levels along the decline of RRF. It is highly unlikely that this increase is due to an increased dietary phosphorus intake as nPNA and total phosphorus mass removal did not change over time. The increased serum phosphorus levels moreover occurred despite a more thorough phosphorus binder therapy. Active vitamin D usage, however, tended to increase over time. This might raise the hypothesis that the increased phosphorus concentrations merely reflect an increased fractional intestinal phosphorus absorption. However, the importance of active vitamin D for phosphorus absorption has been questioned by recent research [25] and moreover, a subgroup analysis in patients free of any active vitamin D therapy revealed essentially the same findings. Secondly, in a cross-sectional analysis including 68 prevalent Caucasian HD patients, we identified age as well as RRF and nPNA as independent determinants of serum phosphorus levels. These observations extend data from a recent short-term prospective study in our unit [26] and are incremental to previous studies [5, 27, 28] . Wang et al. [5] reported a strong association between RRF and nPNA with phosphorus control in a cohort of 252 prevalent Chinese CAPD patients (mean residual glomerular filtration rate <2 mL/min/1.73m 2 ). In addition, and consistent with previous observations, our data show that even a minimal degree of RRF contributes substantially to overall solute clearance (creatinine > phosphorus > urea nitrogen) [3, 5, 17] .
To the best of our knowledge, we are the first to report an association between RRF and FGF-23. The principal physiological stimuli for increased FGF-23 expression both in vitro and in vivo are calcitriol and high dietary phosphate intake [29] . It is believed that a positive phosphate balance triggers an osteocyte 'phosphorus sensor' towards increased release of FGF-23. Although serum phosphorus and FGF-23 levels correlate strongly, there are no data to support that phosphorus itself is the circulating messenger. The present study suggests that kidney disease itself contributes to raising FGF-23 levels directly. FGF-23 levels almost doubled in incident PD patients over a 2-year time period. Changes in dietary intake and active vitamin D therapy cannot explain this increase. Indeed, measures of dietary phosphorus intake remained stable and a similar increase of FGF-23 level was observed in a subgroup of 15 PD patients free of active vitamin D therapy. Moreover, RRF was found to be associated with FGF-23 levels in prevalent HD patients, independent of traditional determinants. Several hypotheses can be raised to explain these intriguing observations [30] . Firstly, the ailing kidney could contribute to a decreased urinary clearance of the hormone. Additional studies are required to investigate the clearance of FGF-23 in chronic kidney disease by cellular uptake, urinary excretion or dialysis. This may, however, require complex tracer techniques. Secondly, the ailing kidney could express a factor that stimulates FGF-23 production. Finally, the ailing kidney could fail to express a factor that inhibits FGF-23 production. RRF, serum phosphorus and calcium levels and active vitamin D therapy explain 69% of the variation in FGF-23 levels in prevalent HD patients. Of note, serum PTH levels were not associated with RRF. Only female gender and increasing age were found to be independently associated with high PTH levels. These findings are in agreement with data from a recent crosssectional study in 890 children and adolescents undergoing chronic PD as well as with data from other series [31] . The underlying mechanisms of the association between female gender and more severe hyperparathyroidism remain unclear. Female gender favours parathyroid cell proliferation, and it is associated with an increased risk of nodular hyperplasia of parathyroid glands in chronic uraemia [32, 33] . Oestrogen might directly or indirectly influence PTH production and secretion, and it has been suggested that women have a larger phosphate burden than men [33, 34] .
Many epidemiological studies have pointed to the association between hyperphosphataemia and high FGF-23 levels and increased cardiovascular mortality and morbidity [14, 35, 36] . In observational studies, preservation of RRF is an independent predictor of survival, both in HD [17, 37] and PD patients [13] . Although preservation of RRF may simply represent a marker of better cardiovascular health, it is tempting to speculate on a causal relationship between RRF and cardiovascular outcomes. RRF facilitates maintenance of an adequate fluid balance, lowers the level of systemic inflammation and better preserves renal endocrine functions [38, 39] . In addition, RRF substantially contributes to the clearance of middle molecules and protein-bound uraemic toxins, both linked to poor cardiovascular outcomes [40] [41] [42] [43] . Last but not least, our data provide additional [5, 44] and strong evidence that RRF is also of utmost importance to achieve adequate phosphorus control in dialysis patients. Loss of RRF goes along with increasing serum phosphorus and FGF-23 levels. Whether FGF-23 is associated with poor outcomes independent of RRF, or vice versa, remains to be clarified.
In conclusion, our data indicate that RRF is an important determinant of FGF-23 and favour the hypothesis that the ailing kidney directly contributes to raising FGF-23 levels. 
